Neupogen (Filgrastim)

Filgrastim binds to the G‑CSF receptor on hematopoietic progenitor cells in the bone marrow. This binding activates intracellular pathways that promote the proliferation, differentiation, and activation of neutrophil precursors, leading to an increase in circulating neutrophils and enhanced immune defense.

The dose of Neupogen is individualized by the prescribing clinician. Factors such as the patient’s weight, the specific indication (e.g., chemotherapy‑induced neutropenia versus stem‑cell mobilization), and the treatment protocol guide the exact amount and frequency of administration.

Data on filgrastim use in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant. Clinicians are advised to discuss the risk‑benefit profile with the patient and consider alternative options when possible.

To place an order, submit an enquiry on the Neupogen product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. The sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics), and any necessary import documentation.

The primary alternative to filgrastim is pegfilgrastim, a pegylated form that has a longer half‑life and is typically administered as a single dose per chemotherapy cycle. Filgrastim (Neupogen) requires daily dosing but offers more flexibility for dose adjustments, whereas pegfilgrastim provides convenience with fewer injections.

Neupogen must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. If the product is inadvertently exposed to temperatures outside this range, it should be discarded.

Neupogen is supplied as a sterile injectable solution and can be given either intravenously or subcutaneously. The preparation is typically diluted with a compatible diluent, and the injection is performed by a qualified healthcare professional following aseptic technique and the prescriber’s dosing instructions.

Serious adverse events include splenic rupture, which presents as sudden abdominal pain, and severe allergic reactions such as anaphylaxis. Acute respiratory distress syndrome (ARDS) and capillary leak syndrome are also rare but potentially life‑threatening complications that require immediate medical attention.

Neupogen is contraindicated in individuals with known hypersensitivity to filgrastim or any of its excipients. Caution is advised for patients with sickle cell disease, severe renal impairment, or those receiving concurrent myelosuppressive therapy, as these conditions may increase the risk of adverse effects.